World Class Immunologist Dr. Herman Waldmann Joins Cell Source's Scientific Advisory Board

NEW YORK, NY -- (Marketwired) -- 06/17/15 -- Cell Source, Inc. (OTCQB: CLCS) a biotechnology company focused on developing cell therapy treatments based on immunotherapy and regenerative medicine, announced today that Dr. Herman Waldman, who served as Department Head and Professor Emeritus of Pathology at the Oxford Medical School and Clinical Director of Oxford's Therapeutic Antibody Centre, has joined the Cell Source Scientific Advisory Board.

Itamar Shimrat, CEO of Cell Source stated, "Dr. Waldmann's immense experience and knowledge in the field of immunology and his success in translating scientific discoveries into treatments will provide the necessary direction and guidance as a member of the Scientific Advisory Board in its efforts to commercialize Dr. Yair's Reisner's important scientific achievements into commercially viable immunology products. Throughout his three decades at Oxford, Dr. Waldman's focus on regulation of immune response and his current interest in reprogramming the immune system to accept histoincompatible stem cell-derived transplants fits very closely with Cell Source's focus on its Veto Cell technology, whose most significant attribute is its tolerance induction capability. We expect Dr. Waldman to act as a leader in terms of both overall development planning and evaluation of specific commercialization opportunities."

Dr. Waldmann stated, "I am very excited to play a key role as a Scientific Advisor for Cell Source and help lead its efforts in commercializing Dr. Reisner's work." Dr. Waldmann gained his BA, MD and PhD at Cambridge, where he was also Professor of Therapeutic Immunology. He is a key figure in the field of immune system regulation. A past winner of the prestigious Starzl Prize in Surgery and Immunology from the Starzl Transplantation Institute at the University of Pittsburg. Dr. Waldmann received a SCRIP Lifetime Achievement Award, one of the most prestigious awards in the biotechnology industry.

His pioneering work in the use of therapeutic monoclonal antibodies to induce immune tolerance was translated into Lemtrada, a Multiple Sclerosis treatment developed by Genzyme (Sanofi) and approved by the FDA after achieving significantly reduced relapse rates of the disease.

Dr. Waldmann has served on multiple advisory boards including the UK Medical Research Council, a UK government agency, the Wellcome Trust, a global charitable organization, and Cancer Research UK, all of which provide major funding of UK biomedical research.

About Cell Source, Inc.

Cell Source, Inc. (OTCQB: CLCS) a biotechnology company focused on developing cell therapy treatments based on immunotherapy and regenerative medicine.

For more information go to www.cell-source.com

Cautionary Note on Forward-Looking Statements

This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. With the exception of historical information, the matters discussed in this press release are forward-looking statements that involve a number of risks and uncertainties. The actual future results of Cell Source, Inc. could differ significantly from those statements. Factors that could cause actual results to differ materially include risks and uncertainties such as the inability to finance the company's operations, inability to hire and retain qualified personnel, and changes in the general economic climate, as well as the risk factors disclosed in Cell Source, Inc.'s Form 10-K filed on March 13, 2015. Cell Source, Inc. may, in some cases, use terms such as "anticipates," "continue," "estimates," "predicts," "believes," "potential," "proposed," "expects," "plans," "intends," "may," "could," "should," "might," "will," or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions. Although we believe that the expectations reflected in the forward-looking statements are reasonable, such statements should not be regarded as a representation by Cell Source, Inc. or any other person, that such forward-looking statements will be achieved. Cell Source, Inc. undertakes no duty to update any of the forward-looking statements, whether as a result of new information, future events or otherwise. In light of the foregoing, readers are cautioned not to place undue reliance on such forward-looking statements. This release does not constitute an offer to sell or a solicitation of offers to buy any securities of any entity.

   INVESTOR, MEDIA & GENERAL CORPORATE CONTACT: Phone:   +1 (646) 612-7554 Toll Free: +1 (888)-315-4650 Email:  [email protected]

Source: Cell Source, Inc.

You May Also Be Interested In

• First High-School Education Group Announces Fiscal Year 2023 Unaudited Financial Results
• ALX Resources Corp. Intersects Additional Uranium Mineralization at the Gibbons Creek Uranium Project, Athabasca Basin, Saskatchewan
• Predictmedix AI Expands Reach and Impact in Healthcare Transformation Efforts